Squarepoint’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
Other funds holding DNTH
FFM
APM
OCA
Squarepoint's DNTH Position: Q2 2026 in Review
Squarepoint sold out of Dianthus Therapeutics (DNTH) in Q2 2026, closing a stake of 38,738 shares — an estimated $3.25M sold.
Squarepoint first reported a position in DNTH in Q1 2020 and held it in 14 quarters. The position peaked at $8.54M in Q4 2025. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.
- Squarepoint reported no remaining Dianthus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Squarepoint sold 38,738 Dianthus Therapeutics shares in Q2 2026, an estimated $3.25M.
- Squarepoint first reported a position in Dianthus Therapeutics in Q1 2020 and held it in 14 quarters.
- Squarepoint's Dianthus Therapeutics position peaked at $8.54M in Q4 2025.
- 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.